Abstract ID:
1
Impact of gender on survival of patients (pts) with hepatocellular carcinoma (HCC): A SEER analysis Dongyun Yang 2 , Josh Usher 2 , Jordan LoCoco 1 , Pritesh Chaudhari 1 , Heinz-Josef Lenz 1,2 , Anthony El-Khoueiry 1 1. Department of Medical Oncology 2. Department of Preventive Medicine University of Southern California/Norris Comprehensive Cancer Center , Los Angeles, CA Hepatocellular carcinoma (HCC) is the second most frequently cause of cancer death worldwide 1 . HCC is significantly more prevalent among males (M) than in females (F). Preclinical models suggest a role for antibody as well as anti-estrogenic therapies in debilitating HCC progression, such as IL-6 suppression or estrogen receptor α-mediated inhibition of NF-κB activity 2-3 . We analyzed gender and age as impacting factors in the overall survival of HCC patients (pts) using SEER registry data. Females below the age of 55 appear to have superior survival compared to males with HCC based on a SEER registry data analysis. This difference in survival is de-accentuated and eventually becomes nonexistent with the aging process, as this shift first emerges in females over the age of 55. Ultimately, total congruence in rates of survival between the sexes is achieved as females reach and surpass 65 years of age. This finding is in line with preclinical reports of Abstract ID: Results Conclusions Introduction Methods 4128 References 1.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69- 90. 2.Yang W, Lu Y, Xu Y, et al. Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). J Biol Chem. 2012;287:40140-9. 3.Xu H, Wei Y, Zhang Y, et al. Oestrogen attenuates tumour progression in hepatocellular carcinoma. J Pathol We identified all patients diagnosed with HCC (ICD-O-3 site code C22.0 and histology code 8170-8175) from 1988 to 2009 from the SEER registry. Pts with information on gender, age, ethnic background, and staging were included in the analysis. The exclusion criteria were following: Hazard ratios (HR) for survival were derived using Cox regression models adjusted for age, sex, race, year of diagnosis, marital status, birthplace, stage, differentiation, tumor size, and treatment
description
Impact of gender on survival of patients (pts) with hepatocellular carcinoma (HCC): A SEER analysis Dongyun Yang 2 , Josh Usher 2 , Jordan LoCoco 1 , Pritesh Chaudhari 1 , Heinz-Josef Lenz 1,2 , Anthony El-Khoueiry 1 1. Department of Medical Oncology - PowerPoint PPT Presentation
Transcript of Abstract ID:
Impact of gender on survival of patients (pts) with hepatocellular carcinoma (HCC): A SEER analysis Dongyun Yang2, Josh Usher2, Jordan LoCoco1, Pritesh Chaudhari1, Heinz-Josef Lenz1,2, Anthony El-Khoueiry1
1. Department of Medical Oncology 2. Department of Preventive Medicine
University of Southern California/Norris Comprehensive Cancer Center , Los Angeles, CA
Hepatocellular carcinoma (HCC) is the second most frequently cause of cancer death worldwide1. HCC is significantly more prevalent among males (M) than in females (F). Preclinical models suggest a role for antibody as well as anti-estrogenic therapies in debilitating HCC progression, such as IL-6 suppression or estrogen receptor α-mediated inhibition of NF-κB activity2-3. We analyzed gender and age as impacting factors in the overall survival of HCC patients (pts) using SEER registry data.
Females below the age of 55 appear to have superior survival compared to males with HCC based on a SEER registry data analysis. This difference in survival is de-accentuated and eventually becomes nonexistent with the aging process, as this shift first emerges in females over the age of 55. Ultimately, total congruence in rates of survival between the sexes is achieved as females reach and surpass 65 years of age. This finding is in line with preclinical reports of estrogen attenuation of HCC development and progression.
Abstract ID:
Results
Conclusions
Introduction
Methods
4128
References1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin 2011;61:69-90.2. Yang W, Lu Y, Xu Y, et al. Estrogen represses hepatocellular carcinoma
(HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). J Biol Chem. 2012;287:40140-9.
3. Xu H, Wei Y, Zhang Y, et al. Oestrogen attenuates tumour progression in hepatocellular carcinoma. J Pathol 2012;228:216-29.
We identified all patients diagnosed with HCC (ICD-O-3 site code C22.0 and histology code 8170-8175) from 1988 to 2009 from the SEER registry. Pts with information on gender, age, ethnic background, and staging were included in the analysis. The exclusion criteria were following:
Hazard ratios (HR) for survival were derived using Cox regression models adjusted for age, sex, race, year of diagnosis, marital status, birthplace, stage, differentiation, tumor size, and treatment and stratified by SEER registry.
